Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Towards Neutron Capture on Exotic Nuclei: Demonstrating (d,pγ) as a Surrogate Reaction for (n,γ).

Ratkiewicz A, Cizewski JA, Escher JE, Potel G, Burke JT, Casperson RJ, McCleskey M, Austin RAE, Burcher S, Hughes RO, Manning B, Pain SD, Peters WA, Rice S, Ross TJ, Scielzo ND, Shand C, Smith K.

Phys Rev Lett. 2019 Feb 8;122(5):052502. doi: 10.1103/PhysRevLett.122.052502.

PMID:
30822004
2.

Constraining Neutron Capture Cross Sections for Unstable Nuclei with Surrogate Reaction Data and Theory.

Escher JE, Burke JT, Hughes RO, Scielzo ND, Casperson RJ, Ota S, Park HI, Saastamoinen A, Ross TJ.

Phys Rev Lett. 2018 Aug 3;121(5):052501. doi: 10.1103/PhysRevLett.121.052501.

PMID:
30118303
3.

Low-energy enhancement in the photon strength of 95Mo.

Wiedeking M, Bernstein LA, Krtička M, Bleuel DL, Allmond JM, Basunia MS, Burke JT, Fallon P, Firestone RB, Goldblum BL, Hatarik R, Lake PT, Lee IY, Lesher SR, Paschalis S, Petri M, Phair L, Scielzo ND.

Phys Rev Lett. 2012 Apr 20;108(16):162503. Epub 2012 Apr 19.

PMID:
22680714
4.

Martial arts: time needed for training.

Burke DT, Protopapas M, Bonato P, Burke JT, Landrum RF.

Asian J Sports Med. 2011 Mar;2(1):31-6.

5.

Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.

Morales JM, Hartmann A, Walker R, Arns W, Senatorski G, Grinyó JM, Shoker A, Wilczek H, Jamieson NV, Lelong M, Brault Y, Burke JT, Scarola JA; Rapamune Maintenance Regimen Study Group.

Transplant Proc. 2009 Jul-Aug;41(6):2339-44. doi: 10.1016/j.transproceed.2009.05.009.

PMID:
19715914
6.

Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients.

Rovira J, Marcelo Arellano E, Burke JT, Brault Y, Moya-Rull D, Bañón-Maneus E, Ramírez-Bajo MJ, Gutiérrez-Dalmau A, Revuelta I, Quintana LF, Campistol JM, Diekmann F.

Transpl Int. 2008 Oct;21(10):992-8. doi: 10.1111/j.1432-2277.2008.00710.x. Epub 2008 Jul 24.

7.

Lifetime measurement of the first excited 2+ state in 16C.

Wiedeking M, Fallon P, Macchiavelli AO, Gibelin J, Basunia MS, Clark RM, Cromaz M, Deleplanque MA, Gros S, Jeppesen HB, Lake PT, Lee IY, Moretto LG, Pavan J, Phair L, Rodriguez-Vietiez E, Bernstein LA, Bleuel DL, Burke JT, Lesher SR, Lyles BF, Scielzo ND.

Phys Rev Lett. 2008 Apr 18;100(15):152501. Epub 2008 Apr 16.

PMID:
18518099
8.

Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression.

Burke JT, Brault Y, Kahan BD, Hricik DE, Grinyó JM, Chapman JR, Polinsky M, Neylan JF.

Transpl Int. 2008 May;21(5):434-40. doi: 10.1111/j.1432-2277.2007.00624.x. Epub 2008 Jan 9.

9.

Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function.

Friend P, Russ G, Oberbauer R, Murgia MG, Tufveson G, Chapman J, Blancho G, Mota A, Grandaliano G, Campistol JM, Brault Y, Burke JT; Rapamune Maintenance Regimen (RMR) Study Group.

Transpl Int. 2007 Sep;20(9):754-60. Epub 2007 Jun 12.

10.

Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.

Legendre C, Brault Y, Morales JM, Oberbauer R, Altieri P, Riad H, Mahony J, Messina M, Pussell B, Martínez JG, Lelong M, Burke JT, Neylan JF; Rapamune Maintenance Regimen Study Group.

Clin Transplant. 2007 May-Jun;21(3):330-6.

PMID:
17488381
11.

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.

Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF.

J Am Soc Nephrol. 2006 Feb;17(2):581-9.

12.

Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.

Russ G, Segoloni G, Oberbauer R, Legendre C, Mota A, Eris J, Grinyó JM, Friend P, Lawen J, Hartmann A, Schena FP, Lelong M, Burke JT, Neylan JF; Rapamune Maintenance Regimen Study Group.

Transplantation. 2005 Nov 15;80(9):1204-11.

PMID:
16314787
13.

Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients.

Böttiger Y, Brattström C, Bäckman L, Claesson K, Burke JT.

Br J Clin Pharmacol. 2005 Nov;60(5):566-9.

14.

Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus.

Campistol JM, Holt DW, Epstein S, Gioud-Paquet M, Rutault K, Burke JT; Sirolimus European Renal Transplant Study Group*.

Transpl Int. 2005 Sep;18(9):1028-35.

15.

Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.

Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT.

Transplant Proc. 2005 Mar;37(2):693-6.

PMID:
15848504
16.

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.

Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF; Rapamune Maintenance Regimen Study Group.

Transpl Int. 2005 Jan;18(1):22-8. Erratum in: Transpl Int. 2005 Mar;18(3):369.

17.

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, Hammond JA, Whisenant T, Lanigan CM, Head SR, Salomon DR.

Am J Transplant. 2004 Nov;4(11):1776-85.

18.

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years.

Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmaz S, Häyry P, Neylan JF; Rapamune Maintenance Regimen Trial.

Am J Transplant. 2004 Jun;4(6):953-61.

19.

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF; Rapamune Maintenance Regimen Trial.

J Am Soc Nephrol. 2004 Mar;15(3):809-17.

20.

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.

Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT; Rapamune Maintenance Regimen Study Group.

Transplantation. 2003 Jul 27;76(2):364-70.

PMID:
12883194
21.

Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation.

Legendre C, Campistol JM, Squifflet JP, Burke JT; Sirolimus European Renal Transplant Study Group.

Transplant Proc. 2003 May;35(3 Suppl):151S-153S.

PMID:
12742488
22.

Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.

Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, Nègre E, Burke JT, Groth CG; Sirolimus European Renal Transplant Study Group.

Am J Transplant. 2002 May;2(5):436-42.

23.

Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients.

Bäckman L, Kreis H, Morales JM, Wilczek H, Taylor R, Burke JT.

Br J Clin Pharmacol. 2002 Jul;54(1):65-8.

24.

The effect of wall thickness on the response of a spherical ionization chamber.

Shortt KR, Bielaje AF, Ross CK, Stewart KJ, Burke JT, Corsten MJ.

Phys Med Biol. 2002 May 21;47(10):1721-31.

PMID:
12069089
25.

Sirolimus and erythromycin interaction: two cases.

Claesson K, Brattström C, Burke JT.

Transplant Proc. 2001 May;33(3):2136. No abstract available.

PMID:
11377477
26.

Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.

Böttiger Y, Säwe J, Brattström C, Tollemar J, Burke JT, Häss G, Zimmerman JJ.

Clin Pharmacol Ther. 2001 Jan;69(1):32-40.

PMID:
11180036
27.

Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers.

Brattström C, Säwe J, Jansson B, Lönnebo A, Nordin J, Zimmerman JJ, Burke JT, Groth CG.

Ther Drug Monit. 2000 Oct;22(5):537-44.

PMID:
11034258
28.

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.

MacDonald A, Scarola J, Burke JT, Zimmerman JJ.

Clin Ther. 2000;22 Suppl B:B101-121. Review.

PMID:
10823378
29.

Pharmacokinetics, brain distribution and pharmaco-electrocorticographic profile of zolpidem, a new hypnotic, in the rat.

Garrigou-Gadenne D, Burke JT, Durand A, Depoortere H, Thénot JP, Morselli PL.

J Pharmacol Exp Ther. 1989 Mar;248(3):1283-8.

PMID:
2703975
30.

Acute injuries of the axis vertebra.

Burke JT, Harris JH Jr.

Skeletal Radiol. 1989;18(5):335-46.

PMID:
2781336
31.

Direct enantiomeric separation of betaxolol with applications to analysis of bulk drug and biological samples.

Krstulović AM, Fouchet MH, Burke JT, Gillet G, Durand A.

J Chromatogr. 1988 Oct 28;452:477-83.

PMID:
2907517
32.

Enantiomeric analysis of a new anti-inflammatory agent in rat plasma using a chiral beta-cyclodextrin stationary phase.

Krstulović AM, Gianviti JM, Burke JT, Mompon B.

J Chromatogr. 1988 Apr 29;426(2):417-24. No abstract available.

PMID:
3392155
33.

Radiology of the urinary system in the emergency department.

Sandler CM, Burke JT.

Emerg Med Clin North Am. 1985 Aug;3(3):507-24. Review.

PMID:
3893979
34.

Determination of antiepileptic drugs.

Burke JT, Thénot JP.

J Chromatogr. 1985 May 10;340:199-241. Review.

PMID:
3926805
35.

Low (type III) odontoid fracture: a new radiographic sign.

Harris JH Jr, Burke JT, Ray RD, Nichols-Hostetter S, Lester RG.

Radiology. 1984 Nov;153(2):353-6.

PMID:
6484166
36.

The sacral foramina.

Jackson H, Burke JT.

Skeletal Radiol. 1984;11(4):282-8.

PMID:
6729502
37.

Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function.

Burke JT, Wargin WA, Sherertz RJ, Sanders KL, Blum MR, Sarubbi FA.

J Pharmacokinet Biopharm. 1982 Dec;10(6):601-14.

PMID:
7182457
38.

[Brief history of post-marketing surveillance of perhexiline maleate].

Burke JT.

Therapie. 1981 May-Jun;36(3):279-80. French. No abstract available.

PMID:
7027522
39.
40.

Rearrangement of chloramphenicol-3-monosuccinate.

Brent DA, Chandrasurin P, Ragouzeos A, Hurlbert BS, Burke JT.

J Pharm Sci. 1980 Aug;69(8):906-8.

PMID:
6249906
41.

Chronopharmacological study of antihistamines in man with special references to terfenadine.

Reinberg A, Levi F, Guillet P, Burke JT, Nicolai A.

Eur J Clin Pharmacol. 1978 Dec 1;14(4):245-52. No abstract available.

PMID:
32044
42.

Inhibitory activity of terfenadine on histamine-induced skin wheals in man.

Hüther KJ, Renftle G, Barraud N, Burke JT, Koch-Weser J.

Eur J Clin Pharmacol. 1977 Nov 14;12(3):195-9.

PMID:
22436

Supplemental Content

Loading ...
Support Center